News & Events

SOUTH SAN FRANCISCO, CA (June 7, 2012) - KaloBios Pharmaceuticals, Inc. today announced the appointment of Néstor A. Molfino, M.D. as Chief Medical Officer.  Dr. Molfino was previously Vice President, Clinical Development and Respiratory Therapeutic Area Head at MedImmune, Inc. (AstraZeneca Biologics).

“Néstor Molfino joins KaloBios with 18 years of experience directing clinical development at leading international biopharmaceutical companies, both in the United States and Canada,” said David Pritchard, KaloBios’ President and Chief Executive Officer. “His strong expertise in pulmonary medicine will be particularly beneficial in advancing our clinical development of KB001-A in cystic fibrosis and KB003 in severe asthma.”

Prior to joining MedImmune, Dr. Molfino was Senior Director, Clinical Development at Otsuka Maryland Research Institute from 2003-2007. Previously, he held the positions of Director, Medical Affairs at Baxter Bioscience from 2000-2003, and Vice President, R&D and Scientific Affairs at Theratechnologies, Inc., a Montreal-based biotechnology start-up. Earlier in his career, Dr. Molfino was Director, Clinical Research at Abbott Laboratories and began his industry career at Boehringer Ingelheim. Dr. Molfino received his M.D. degree from the Universidad Nacional de Rosario, Argentina and an M.Sci. degree from the University of Toronto/Mount Sinai Research Institute. He is a Fellow of the Medical Research Council of Canada.

About KaloBios
KaloBios Pharmaceuticals, Inc., a South San Francisco, California based private company, is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies (mAbs) designed to significantly improve the lives of seriously ill patients with difficult-to-treat diseases.

Currently, KaloBios has three Investigational New Drug development programs:

·         KB001-A, an anti-PcrV mAb fragment, is partnered with Sanofi Pasteur and is being developed for the treatment and prevention of Pseudomonas aeruginosa (Pa) infection.   KaloBios retained rights to cystic fibrosis and plans to initiate a Phase 2 study in patients with chronic Pa infection.

·         KB003, an anti-GM-CSF mAb with potential to treat inflammatory diseases is being developed for the treatment of asthma.  KaloBios plans to initiate a Phase 2 study in asthma uncontrolled by corticosteroids.

·         KB004,  a mAb targeting the EphA3 tyrosine kinase receptor, has potential utility in treating hematologic malignancies and solid tumors. KaloBios is currently testing this drug in a Phase 1 study in hematologic malignancies.

All our antibodies were generated using our proprietary Humaneered™ technology, a method that converts nonhuman antibodies (typically mouse) into engineered, human antibodies that have a high binding affinity to their target and are designed for chronic therapeutic use.  We believe that antibodies produced with our Humaneered™ technology offer important clinical and economic advantages over antibodies generated by other methods, in terms of high binding affinity, high manufacturing yields, and minimal to no immunogenicity (inappropriate immune response) upon repeat administration.

For more information, visit http://www.kalobios.com.

###

Media Contact:

Joan E. Kureczka
Kureczka/Martin Associates
Tel:  (415) 821-2413

Mobile: (415) 690-0210
Joan@Kureczka-Martin.com